MyerL, PhillipsTK, McIntyreJA, et al.HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa. HIV Med, 2017; 18(2):80–88.
2.
De SantisM, CarducciB, De SantisL, et al.Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med, 2002; 162(3):355.
3.
ZashR, MakhemaJ, ShapiroRL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med, 2018; 379(10):979–981.
4.
FordN, MofensonL, ShubberZ, et al.Safety of efavirenz in the first trimester of pregnancy: An updated systematic review and meta-analysis. AIDS, 2014; 28Suppl 2:S123–S131.
5.
Barlow-MoshaL, SerunjogiR, KalibbalaD, et al.Prevalence of neural tube defects, maternal HIV status, and antiretroviral therapy from a hospital-based birth defect surveillance in Kampala, Uganda. Birth Defects Res, 2022; 114(3–4):95–104.
6.
TownsendCL, ByrneL, Cortina-BorjaM, et al.Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011. AIDS, 2014; 28(7):1049–1057.
7.
BriandN, JasseronC, SibiudeJ, et al.Cesarean section for HIV-infected women in the combination antiretroviral therapies era, 2000–2010. Am J Obstet Gynecol, 2013; 209(4):335.e1-.e12.
8.
KourtisAP, EllingtonS, PazolK, et al.Complications of cesarean deliveries among HIV-infected women in the United States. AIDS, 2014; 28(17):2609–2618.
9.
Nielsen-SainesK, WattsDH, VelosoVG, et al.Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med, 2012; 366(25):2368–2379.
10.
FlynnPM, TahaTE, CababasayM, et al.Association of maternal viral load and CD4 count with perinatal HIV-1 transmission risk during breastfeeding in the PROMISE postpartum component. J Acquir Immune Defic Syndr, 2021; 88(2):206–213.
